Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients

Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: حمید طیبی خسروشاهی , سیما عابدی آذر , جاوید صفا , سیدصدرالدین راثی هاشمی , جلال اعتمادی خیاوی , حمید نوشاد عباسپور

کلمات کلیدی: Anemia; Biosimilar; Eprex; Hemodialysis; Pastopoitin.

نشریه: 30931 , 5 , 23 , 2015

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله سیما عابدی آذر
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات کلیه
کد مقاله 72754
عنوان فارسی مقاله Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
عنوان لاتین مقاله Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
ناشر 13
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Background: The efficacy of human recombinant erythropoietins (rHuEPOs) in the treatment of anemia with different etiologies is proven. Development of biosimilar rHuEPO products with lower cost and wider availability is important for the care of anemic patients. Objective: The aim of the present study was to determine the bioequivalence and safety of a biosimilar rHuEPO (Pastopoitin(®)) and compare it with the innovator product Eprex(®), as a standard rHuEPO. Methods: One hundred and seven anemic patients on stable hemodialysis were recruited to this randomized double-blind comparative trial and assigned to either subcutaneous Pastopoitin (n = 50) or Eprex (n = 57). Each study group received rHuEPO at a dose of 80-120 IU/kg/week in 2-3 divided doses for a period of 3 months. Hematologic parameters including Hemoglobin, hematocrit, RBC, EBC, platelet, MCV, MCH and MCHC were checked every 2 weeks. Blood iron, ferritin, TIBC, creatinine, BUN and electrolytes (Na, K, Ca and P) were evaluated monthly over the 3 months. Results: A significant increase in hemoglobin, hematocrit and RBC was observed by the end of study in both Pastopoitin and Eprex groups (p < 0.001). However, these factors were not significantly different between the groups, neither at baseline nor at the end of study (p > 0.05). Likewise, the groups were comparable regarding MCV, MCH, MCHC, iron, ferritin, TIBC, creatinine, BUN and electrolytes at baseline as well as at the end of trial. Adverse events were not serious and occurred with the same frequency in the study groups. Conclusion: Pastopoitin showed comparable efficacy and safety profile with Eprex in anemic patients on hemodialysis. Hence, Pastopoitin may be considered as a rHuEPO with a lower cost and wider availability compared with the innovator product Eprex.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
حمید طیبی خسروشاهیهفتم
سیما عابدی آذرهشتم
جاوید صفانهم
سیدصدرالدین راثی هاشمیدهم
جلال اعتمادی خیاوییازدهم
حمید نوشاد عباسپورسیزدهم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
91137976.pdf1399/07/14385927دانلود